**SHARED CARE GUIDELINE**

**Drug:** Riluzole

### Introduction

**Indication:**
To extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other form of motor neurone disease.

Riluzole should only be initiated by a neurological specialist with expertise in the management of motor neurone disease (MND) (as per NICE TA 20, 2001).

It is expected that most patients will be managed by secondary care however this guideline is for those patients who need to be managed in community.

**Background:**
ALS is the most common variant of MND accounting for 65% to 85% of all cases. It is a progressive, fatal neurodegenerative disorder with a median survival of 37 to 49 months. It is characterised by progressive deterioration of muscle tissue (amyotrophy), resulting in both upper and lower motor neurone signs.

Death usually results from ventilatory failure, resulting from progressive weakness and wasting of respiratory and bulbar muscles within approximately 3 years of the onset of symptoms. Although the pathogenesis of ALS is not completely elucidated, it is hypothesised that excessive stimulation of glutamate receptors on neurones may cause or play an important role in the destruction of motor neurones in MND.

In vitro, riluzole inhibits the release of glutamate; decreases firing of motor neurones induced by glutamate receptor agonists and thus protects cells from glutamate-mediated damage.

Riluzole is the only drug currently licensed for the treatment of ALS however symptomatic management, supportive, and palliative care are also available for patients with ALS.

### Dose & Administration

Available as 50mg tablets or 5mg/ml suspension.

**The recommended dose is 50mg twice a day, 12 hours apart, on an empty stomach** (1hour before or 2 hours after food).

Absorption may be affected by fatty food. (See NEWT Guidelines)

**The liquid formulation** should be reserved for use in patients identified by specialist nurses who have bulbar symptoms and risk of dysphagia or bulbar symptoms and poor compliance secondary to dysphagia

The suspension must be gently shaken for at least 30 seconds by rotating the bottle by 180° until it has an appearance of even consistency.

A syringe-adaptor is supplied with the suspension for measurement (follow product information sheet for further instructions on use and wash the syringe with tap water after use). NB: after 1st opening the liquid should be used within 15 days.

Patients should be aware that they will not experience any subjective benefit from taking the medication and may experience unwanted side effects.

### Secondary Care Responsibilities

1. Confirm the diagnosis of MND
2. Assess the need for and appropriateness of riluzole
3. Discuss the benefits and side effects of treatment with the patient.
4. Perform pre-treatment screening (full blood count and serum transaminases)
5. Prescribe and monitor riluzole for 12 months to establish efficacy and safety (see MONITORING below)
6. Write to the patient’s GP and ask if they are willing to take part in shared care. GPs should take on prescribing if they feel competent to do so. If shared care is agreed, share patient treatment plan.
7. Review the patient every three months to monitor the patient’s response to therapy.
8. Request copies of test results for the patient's GP by completing the “copy to” section on the pathology form.
9. Advise patients or their carers how to recognise signs of neutropenia and advise them to seek immediate medical attention if symptoms such as fever occur
10. Ensure that clear backup arrangements exist for GPs to obtain advice.
11. Promptly inform the GP of any changes in treatment or treatment plan following hospital admission / out-patient consultation / ad hoc patient consultation
## Primary Care Responsibilities

1. Provide the patient with prescriptions for riluzole 50mg tablets after the initial minimum 12 months treatment
2. Monitor the patient’s overall health and well being and report signs of disease progression to the consultant or the specialist nurse
3. Arrange ongoing monitoring at the recommended frequencies (see MONITORING below)
4. Request copies of test results for the patient’s consultant by completing the “copy to” section on the pathology form.
5. Report any adverse events to the consultant or specialist nurse and stop treatment on their advice or immediately if an urgent need arises
6. Report any serious suspected adverse events to the MHRA
7. Advise patients and their carers on how to recognise signs of neutropenia and to seek immediate medical attention if symptoms such as fever occur
8. **Report any febrile illness** to the specialist team and check the white blood cell count
9. Symptomatic management of minor adverse effects

## Monitoring

At introduction of the drug FBC (including differential WBC), U&E and LFT (incl ALT) monthly for the first three months of treatment then three monthly up to one year – more frequently if patient develops raised ALT levels

After the initial minimum 12 months prescribed by secondary care:
- FBC (including differential WBC) and LFTs repeated annually
- Discontinue riluzole and seek advice if:
  - ALT levels increase to five times the upper limit of normal range (≥ 225 IU/l)
  - There is evidence of neutropenia

## Adverse Effects

The most common side effects are:
- Gastrointestinal upsets including nausea, anorexia, constipation, diarrhoea
- Tiredness and fatigue (asthenia)
- Headache, dizziness, somnolence (patients should be warned about not driving or operating machinery if affected)
- Tachycardia
- Elevation of ALT levels

It is estimated that approximately 10% of patients are likely to experience side effects of such intensity that they consider discontinuing the drug.

Anaphylactoid reaction, angio-oedema, neutropenia and pancreatitis have been reported rarely

If respiratory symptoms develop e.g. dry cough and/or dyspnoea, chest radiography should be performed, and in case of findings suggestive of interstitial lung disease (e.g. bilateral diffuse lung opacities), riluzole should be discontinued immediately.

Any reports of febrile illness should result in discontinuation of riluzole and differential FBC to assess for neutropenia

Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur

Always consult the latest version of the Summary of Product Characteristics (SPC) at [www.medicines.org.uk](http://www.medicines.org.uk) for full details

## Common Drug Interactions

There have been no clinical studies to evaluate the interactions of riluzole with other medicinal products.

However, as Riluzole is metabolised by the liver, there is a possibility that it may interact with:
- CYP1A2 inhibitors that may potentially decrease the rate of riluzole eliminations e.g. diclofenac, diazepam, clomipramine, imipramine, theophylline, amitriptyline and quinolones
- CYP1A2 Inducers that could increase the rate of riluzole elimination e.g. cigarette smoke, charcoal broiled food, rifampicin and omeprazole.

## Contraindications

- Previous history of liver disease or if their baseline ALT/AST levels are greater than three times the upper limit of normal
- Impaired renal function (no relevant data.90% dose excreted in urine)
- Previous allergic reaction to Riluzole
- Neutropenia
- Signs of dementia and/or major psychiatric disorders
- May be pregnant or are breastfeeding
- Unlikely to comply with the requirements of treatment i.e. blood tests

---

**This guidance does not replace the SPC, which should be read in conjunction with this guidance.**
**Version Control**

<table>
<thead>
<tr>
<th>Version Number</th>
<th>Amendments</th>
<th>Author</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1.0</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; Version approved</td>
<td></td>
<td>December 2015</td>
</tr>
<tr>
<td>Version 1.1.</td>
<td>Liquid formulation incorporated</td>
<td>SMcK Midlands &amp; Lancashire CSU</td>
<td>March 2016</td>
</tr>
</tbody>
</table>

**RELEVANT CONTACT LIST**

**Neurology**

**Dr David Footit**  
Consultant Neurologist, UHMB

**Dr John Nixon**  
Consultant Neurologist, Royal Preston Hospital

**Dr Majeed**  
MND Care Centre Director RPH

**MND Care Centre Team**  
Royal Preston Hospital  
Ward 17, Sharoe Green Lane  
Fulwood, Preston  
PR2 9HT

**References**

Riluzole SPC available at [www.medicines.org.uk](http://www.medicines.org.uk)  
NICE TA 20  
NEWT guidelines, UKMI